

**Suppl. Table 1.** Association between *ZNF471* methylation and clinicopathological parameters of ESCC patients.

Clinicopathological features	Numbers (N=79)	ZNF471 methylation status		p value
		Methylated	Unmethylated	
<b>Age</b>				0.779
<63	46	25	21	
≥63	33	19	14	
<b>Gender</b>				0.613
Male	63	36	27	
Female	16	8	8	
<b>Tumor Location</b>				0.970
Upper	16	11	5	
Middle	46	20	26	
Lower	16	12	4	
Unknown	1	1	0	
<b>Differentiation</b>				0.649
Moderately/Well	72	40	32	
Poorly	7	4	3	
<b>Tumor Grade</b>				0.457
T1–2	28	14	14	
T3–4	51	30	21	
<b>Tumor Size</b>				0.571
>5.0 cm	6	2	4	
≥2.0 cm ≤5.0 cm	64	37	27	
<2.0 cm	4	2	2	
Unknown	5	3	2	
<b>Tumor Stage</b>				0.971
I/II	54	30	24	
III/IV	25	14	11	
<b>Lymph Nodes</b>				
<b>Metastasis</b>				0.710
Positive	22	13	9	
Negative	57	31	26	
<b>Distant Metastasis</b>				0.376
Positive	1	1	0	
Negative	78	43	35	

$\chi^2$  and Fisher exact tests were used.

**Suppl. Table 2.** Primers used in this study

PCR	Primer	Sequence (5'-3')	Product size (bp)	PCR cycles	Annealing temp. (°C)
RT-PCR	ZNF471F	GAGATGACGAGTGAGATGAC	194bp	32	55
	ZNF471R	TGACTTCCCATCTGCTTCTC			
qRT-PCR	GAPDHF	CCAGCAAGAGCACAAAGAGGAA	114bp	23	55
	GAPDHR	GGTCTACATGGCAACTCAAGG			
	MAPK10F	CATCCCTACATCAACGTCTG	249bp		60
	MAPK10R	GGAGGAGATGTCATTGACAG			
	SAMD9LF	GCTAGAAGCTCTGAGAGCAGA	116bp		60
	SAMD9LR	TGCTGCAGTAGGAAGGCATA			
	TUSC3F	GTATGGTGGACTATGATGAGGG	120bp		60
	TUSC3R	TGGAGGTCAAAAGTATCAGCTC			
	IFNL3F	GCTGCCACATAGCCCAGTTC	157bp		60
	IFNL3R	CTCACCTGCAGCTGCCTCA			
	PNMTF	CTCATCGACATTGGTTCAGGC	175bp		60
	PNMTR	TGAGGCAGGCATGTTGGCTG			
	PYCARDF	CAAGCTGAAGCTGCTGTCTG	162bp		60
	PYCARDR	CCATGTGCGCGCAGCACGT			
	FOSBF	GGCGACCCCTTCCCCGTTGT	102bp		60
	FOSBR	ACTGCCGCTGGTGCCTTGG			
	IL1BF	GCCTGAAGCCCTTGCTGTAGT	51bp		60
	IL1BR	GCGGCATCCAGCTACGAAT			
	CNTN1F	GTTGCTGGTCAGTCATCTTGTG	140bp		60
	CNTN1R	TGGTATTGATTGGCTGCTCTTC			
	CDH12F	AGCAGACTTTAGCCACAGAGC	182bp		60
	CDH12R	AGTGCCCTCTCCCTTGCTA			
	CDH19F	GTCAAGCAGCCAGTGCGATCT	169bp		60
	CDH19R	CAGCTCCAGCTCCAAAAGC			
	PCDH8F	CGACAGCGATTCCGACATCA	273bp		60
	PCDH8R	CTCTGCAGCCCCACTGTCTT			
	PCDH9F	CTGTTGGCTGCTCTGATTGC	148bp		60
	PCDH9R	CTGTGGCAGCATTGATGTGAG			
PCDH10F	ACTGCTATCAGGTATGCCTG	219bp		60	
PCDH10R	GTCTGTCAACTAGATAGCTG				
PCDH17F	TGGAGGAGAGGAACGCCATG	299bp		60	
PCDH17R	AACAACTGCTGCCTGCTGC				
PCDH18F	CACGATGTAAGTGGCAAGAAT	138bp		60	
PCDH18R	GGCTCGAAATCGAACAGTAG				

	PCDHA1F	CTCCAAGTCTTAACACGTCAGA	124bp	60
	PCDHA1R	CTGTGCATGCCTGCTCTCAG		
	PCDHB15F	GACCGTCTGTTAATTTTGTCTTCC	129bp	60
	PCDHB15R	CAGACAAAGGAAATGAGTAACAT		
	PCDHB6F	AGCCATTCACTTATGCATATTT	124bp	60
	PCDHB6R	GCTCACAAACTAATGTGTTGACA		
	PCDHB8F	GGAGCCTGTCTCAGAACTATCAGT	124bp	60
	PCDHB8R	ACTGGTTTCAGGAACTGGAECTCA		
	PCDHB12F	GGGAGAACCTAGAAGCCATTCAAC	124bp	60
	PCDHB12R	CGCAGTTGTGGGAAACGT		
	PCDHB14F	GGACATTTTGGAGAGAACTG	124bp	60
	PCDHB14R	GTAAGGCCTTCTAAAAGATAATTG		
	PCDHGA5F	GCGAGCCTCTTCTGATGTCTGATA	124bp	60
	PCDHGA5R	GAGAAACGCCAGTCCGTGTTG		
	PCDHGA7F	TGCTAACATCCGTAGATTTTCAGG	124bp	60
	PCDHGA7R	GAGAAACGCCAGTCCGTGTTG		
<b>MSP</b>	ZNF471m44	TTTTGTTTTCGTTTTTTTCGTTC	223bp	60
	ZNF471m6	ACGCGACTAAACCTTCGCG		
	ZNF471u44	GTTTTGTTTTGTTTTTTTGTTC	228bp	58
	ZNF471u6	AAAAACACAACCTAACCTTCACA		
<b>ChIP assay</b>	MAPK10proF1	GAGAAGAGGAGCAGCATCTC	127bp	
	MAPK10proR1	AGGCGTCGAGCACAGTAGGG		
	MAPK10proF2	CCCTACTGTGCTCGACGCCT	164bp	
	MAPK10proR2	GTGACACACCATGCTCACG		
	MAPK10proF3	CGTGAGCATGGTGTGTAC	158bp	
	MAPK10proR3	AGCTCGGGTGGGAGATCT		
	MAPK10proF4	AGATCTCCCACCCCGAGCT	180bp	
	MAPK10proR4	CGCTCGGTCACCAACCTGA		
<b>Dual-luciferase report assay</b>	MAPK10procF	CTAGCCCGGGCTCGAGCGAAAGC AGAGAGAGGAGGAA	860bp	
	MAPK10procR	CCGGAATGCCAAGCTTCAGGCGCT AGGAACTCTGC		

## **Supplementary Figure legends**

**Supplementary Fig 1.** Correlation analysis of expression and promoter methylation status of ZNF471 in ESCC tissue samples from The Cancer Genome Atlas (TCGA).

**Supplementary Fig 2.** Cell migration abilities of ESCC cells, evaluated by wound healing assays. Photographs were captured at 0, 12 and 24 h. Representative wound healing ratio is shown. Scale bars: 200  $\mu\text{m}$ .

**Supplementary Fig 3.** Expression and location of E-cadherin and Vimentin markers in ESCC cells, as detected by confocal microscopy. Scale bars: 10  $\mu\text{m}$ .


**Supplementary Fig 4.** (A, B) MAPK10 expression level in ZNF471-stably transfected KYSE410 cells, shown by visualization graphs and histogram (C) KEGG pathway categories of differentially expressed genes. The rich factor represents the proportion of differentially expressed genes within a specific term, and the size of the point represents the number of related differentially expressed genes. The q-value is the calibrated p value.

**Supplementary Fig 5.** Correlation analysis of expression of ZNF471 and MAPK10 in ESCC tissue samples from The Cancer Genome Atlas (TCGA).


**Supplementary Fig 6.** % input of MAPK10 DNA by anti-histone H4 acetylcholine antibody and anti-histone H2A phosphorylation were determined by ChIP-qPCR.

**Supplementary Fig 7.** The effect of ZNF471 on MAPK10/JNK3 signaling, as determined by luciferase reporter activity assays in 293T cells. The pLG3-Tr1 plasmid corresponds to all ChIP primer regions, the pLG3-Tr2 truncated plasmid corresponds to the ChIP primer F1/R1 and F2/R2 regions, the pLG3-Tr3 truncated plasmid corresponds to the ChIP primer F3/R3 region, and the pLG3-Tr4 truncated plasmid corresponds to the ChIP primer F4/R4


region.  
sFig 1.





sFig 2.



sFig 3.




sFig 4.






sFig 5.




sFig 6.

**MAPK10  
proF2/R2**



**MAPK10  
proF3/R3**



sFig 7.

